Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 211 participants.

Also called NCT01912534

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 211 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01912534
Other papers using this trial's data
  • Body Mass Index, Valsartan, and Myocardial Remodeling in Early-Stage Hypertrophic Cardiomyopathy: A Secondary Analysis of the Randomized VANISH Trial Journal of the American Heart Association, 2026-10-20 DOI, PubMed 42858009
  • Cardiac Remodeling in Subclinical Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial JAMA cardiology, 2023-11-01 DOI, PubMed 37672268, PMC10483382 Not in the PMC Open Access subset.
  • Proteomic Analysis of Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Clinical Trial Circulation. Heart failure, 2025-06 DOI, PubMed 40340372, PMC12173761 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH Trial Circulation. Heart failure, 2024-08 DOI, PubMed 39087355, PMC11335449 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Valsartan and Cardiac Remodeling in Early-Stage Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial Cardiac Magnetic Resonance Substudy JAMA cardiology, 2025-06-01 DOI, PubMed 40042824, PMC11883577 Not in the PMC Open Access subset.
  • Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial Nature medicine, 2021-10 DOI, PubMed 34556856, PMC8666141 In the PMC Open Access subset under a licence that is not Creative Commons.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01912534. Randomized; triple masking; primary purpose treatment. Start 2014-03 (actual); primary completion 2019-07 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Acronym
VANISH
Condition
Hypertrophic Cardiomyopathy
Intervention (Drug)
Valsartan
Intervention (Drug)
Placebo
Lead sponsor
Carelon Research (class: other)
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct01912534
Content hash
fd59c085a8cb71dc11ee44c2913e07af32e0e1e015efc1b99ae04463160b0b1d